Radiopharm reports partial response in RAD204 cancer drug trial

July 22, 2026 7:05 AM

Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) reported updated clinical results from the third dosing cohort of its Phase 1 trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found